In a phase 2 trial in participants with obesity and MASLD, once-weekly treatment with the GIP/GLP-1/GCG triple agonist retatrutide resulted in substantial reductions in liver fat, body weight, abdominal visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (ASAT), serum lipids
The tirzepatide before and after results and comparable retatrutide data suggest that the glucagon receptor component produces additional fat loss beyond what dual agonist therapy achieves, particularly for visceral fat
If you are sensitive to stimulants, or if you have trouble sleeping, you may want to avoid taking Acetyl L-Carnitine, or at least avoid taking it before bedtime
Retatrutide once weekly for the treatment of obesity
feline airways, in general, are more sensitive to acetylcholine and serotonin than histamine
Importantly, these studies demonstrate a consistent pattern: whilst retained gastric contents are significantly more common in GLP-1 RA users, the absolute rates vary considerably depending on patient factors, medication duration, and assessment methods [35]
